These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8880873)

  • 21. Single-chain, urokinase-type plasminogen activator in a tumor model linked to metastatic potential.
    Kellen JA; Mirakian A; Wong A
    In Vivo; 1988; 2(2):155-7. PubMed ID: 2979833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen activators and cancer.
    Duffy MJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):681-7. PubMed ID: 2133247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of plasminogen activators and oncogenes to tumour invasion.
    Gelister JS; Boulos PB; Gaffney PJ; Mahmoud M; Lewin MR
    Eur J Surg Oncol; 1990 Feb; 16(1):54-9. PubMed ID: 2155139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of plasminogen activators in cancer dissemination. Clinical perspectives].
    Alonso DF; Bal de Kier Joffé E
    Medicina (B Aires); 1992; 52(3):252-6. PubMed ID: 1342692
    [No Abstract]   [Full Text] [Related]  

  • 27. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
    J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva.
    Parolini S; Rosa D; Flagiello D; Bonardi F; Rampinelli F; Bianchi UA; Molinari Tosatti MP
    Int J Tissue React; 1994; 16(5-6):251-8. PubMed ID: 7558669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
    Masson V
    Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
    Nip J; Rabbani SA; Shibata HR; Brodt P
    J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
    Ferrier CM; de Witte HH; Straatman H; van Tienoven DH; van Geloof WL; Rietveld FJ; Sweep CG; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Mar; 79(9-10):1534-41. PubMed ID: 10188903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasion and metastasis.
    Carr I; Orr FW
    Can Med Assoc J; 1983 May; 128(10):1164-7. PubMed ID: 6340812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase-type plasminogen activator in human aqueous humor.
    Bernatchez SF; Tabatabay C; Belin D
    Invest Ophthalmol Vis Sci; 1992 Aug; 33(9):2687-92. PubMed ID: 1639615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
    Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
    Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Multiscale Mathematical Model of Tumour Invasive Growth.
    Peng L; Trucu D; Lin P; Thompson A; Chaplain MA
    Bull Math Biol; 2017 Mar; 79(3):389-429. PubMed ID: 28210916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A possible role for enzymes in tumour-cell invasion.
    van Aswegen CH; du Plessis DJ
    Med Hypotheses; 1997 May; 48(5):443-7. PubMed ID: 9185134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.
    Entschladen F; Drell TL; Lang K; Joseph J; Zaenker KS
    Lancet Oncol; 2004 Apr; 5(4):254-8. PubMed ID: 15050959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of tissue plasminogen activator by metastasis-inducing S100P protein.
    Clarke CJ; Gross SR; Ismail TM; Rudland PS; Al-Medhtiy M; Santangeli M; Barraclough R
    Biochem J; 2017 Sep; 474(19):3227-3240. PubMed ID: 28798096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.